BioSpace News Archive

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the fourth quarter of 2020.

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today announced that it will release financial results for the third quarter of 2020 after the close of trading on Wednesday, November 4, 2020

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2020, on Wednesday, October 28, 2020. The Company will conduct an earnings call at 8:00 am ET on Thursday, October 29, 2020, where senior management will discuss the Company’s performance and ans

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the third quarter ended September 30, 2020 . All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS). The fo

The rapid increase in lifestyle ailments, rising expenses of healthcare, and increasing number of elderly population have incited various medical insurance organizations and healthcare sector to innovate.

Tetra will leverage its recent Dronabinol data pack acquisition to rapidly file its second New Drug Submission application to commercialize another THC-based prescription drug

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced it will host a webinar exploring the use of a common clinical measure, Event-Related Potential P300 latency (P300), as an assessment of working memory processing speed

BridgeBio Pharma, Inc. (Nasdaq: BBIO) and the University of Colorado Anschutz Medical Campus today announced a collaboration to advance novel research on genetically driven diseases into therapeutic applications for patients.

AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced the formation of a Scientific Advisory Board (SAB) including three of the leading global experts in exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

ILiAD Biotechnologies, LLC (ILiAD), a company utilizing proprietary B-Tech technology to develop next generation infectious disease vaccines, today announced that it will be presenting at the European Society for Paediatric Infection Diseases (ESPID) 2020 Virtual Meeting to be held virtually October 26 – 29, 2020.